CARCLO PLC (CAR) — Investment Research Note

Executive summary

Carclo is a UK-listed precision engineering group manufacturing high-tolerance injection-moulded plastic components (CTP division, ~86% of revenue) for life sciences (diagnostics, drug delivery) and precision machined aerospace parts (Speciality division, ~14%). After a near-death experience — trading suspended August 2025 pending a delayed audit, share price crash, historic contract cancellations — a turnaround under CEO Frank Doorenbosch (appointed 2022) has restored margins to target (10% Return on Sales, 25% ROCE achieved a year ahead of plan) with FY26 revenue ~£114m and rising underlying EBIT. The single most important valuation point today is that a £44.7m IAS 19 pension deficit and multi-decade contribution schedule (£3.5m p.a. to 2029, then indexed £5.8m to 2037) create a real economic liability roughly 1.5× the market cap that must be netted from any enterprise valuation.

Fair value estimate

Fair value range: 30p – 50p per share (implied market cap £22m – £37m); mid ~40p.

Methodology — EV / EBITDA sum-of-parts:

• FY26 underlying EBITDA: H1 delivered £8.6m; historically H2 is stronger (customer shutdowns weight H1), so FY26 EBITDA plausibly £17–19m 2025-11 HY report, 2026-04 trading update.
• Applying 5.0–6.0× EV/EBITDA (typical small-cap UK precision industrial with pension overhang) → EV £90m – £108m.
• Deduct FY26 year-end net debt £24m 2026-04 trading update and a risk-adjusted present value of pension contributions (£40–50m, being ~£3.5m for 3 years + indexed £5.8m for 8 years, discounted).
• Residual equity value £20m – £37m → 30p – 50p per share.

Cross-check (P/E): FY25 underlying EPS 4.3p; FY26 tracking toward ~5–6p with H1 at 0.9p and stronger H2. At 8–10× P/E → 40–60p, consistent with the SOTP.

Current market cap £28.6m sits inside the range, at ~38.9p. Absolute upside to mid ~3%; the stock is broadly fair value, not offering a margin of safety after its ~80× rally from a distressed base over 12 months.

Sector context

Confirmed sector: Industrial Goods & Services (precision engineering / plastics). Listed peers in adjacent precision-manufacture UK small-cap space include TT Electronics, Trifast, Volex and, for the aerospace machining piece, Avon Technologies. Carclo's quality is below typical scaled peers on balance-sheet strength (pension deficit is uncommonly large relative to enterprise value) but in line on operating margins post-turnaround. Growth profile is below peers — the company is deliberately shrinking to a higher-quality core.

Investment thesis (3 bullets)

• Turnaround delivered ahead of plan. ROS reached 10.1% and ROCE 28.8% on a TTM basis at HY26, both ahead of the 10%/25% medium-term targets set in 2023 2025-11 HY report. Underlying operating profit +61% H1YoY on lower revenue, evidencing genuine operational improvement.
• Refinancing removes an existential risk. April 2025 replaced HSBC with a 3-year £36m BZ Commercial Finance facility to April 2028, plus a formalised pension deficit recovery plan — the shares were suspended pending audit as recently as August 2025 2025-08 suspension, 2025-09 restoration. Going-concern uncertainty is now materially reduced.
• Regulated end-market exposure (life sciences + aerospace) with contract renewal visibility. Major customer contract renewed July 2025 for 5 years; Speciality division delivered double-digit growth in aerospace 2025-11 HY report, 2026-04 trading update. "Precision 2030" plan to be unveiled at FY26 full-year results provides catalyst.

Key risks (3 bullets)

• Pension deficit and cash drag. IAS 19 net liability £44.7m at HY26 2025-11 HY report — larger than the entire market cap. Annual contributions of £3.5m to March 2029 rising to indexed £5.8m to March 2037 consume roughly a third of underlying operating profit. Any adverse move in discount rates could rapidly widen the accounting deficit.
• Small, concentrated customer base with historic execution failures. Cancellation of a leading global OEM supply contract in December 2022 caused a profit warning; the delayed FY25 audit forced share suspension in August 2025 2025-07 delay announcement. Concentration risk with a small number of blue-chip life-sciences customers is explicitly cited as a principal risk.
• Very high effective tax rate. Underlying ETR was 61.5% at HY26 and 35–45% guided for FY26 2026-04 trading update because UK losses cannot be recognised for deferred tax and there is withholding tax on foreign dividends/royalties. This structurally suppresses per-share earnings translation from operating profit.

Operating leverage

Carclo has moderate operating leverage — meaningful, but capped by the pension cash drag. HY26 shows the mechanic clearly: revenue fell 6.1% (£61.0m → £57.2m) yet underlying operating profit rose 61% (£3.4m → £5.5m) as manufacturing process optimisation and closure of unprofitable US sites (Tucson) took cost out 2025-11 HY report. Fixed-cost base sits in property, plant and equipment of ~£33m and central overheads of ~£3m per half. A 10–20% revenue beat on the current £114m base would likely add ~50–75% to operating profit — CTP delivered 21.6% return on sales in Speciality in H1 vs 9.6% group, showing what higher-margin volume looks like. However, this incremental profit largely goes to pension contributions and interest (£3.7m half-year net finance cost) before reaching EPS, dampening equity-holder torque.

Value-trap signals

• Persistent pension deficit structurally larger than market cap — a genuine, permanent cash claim on the enterprise.
• Delayed FY25 audit and share suspension (August 2025) is a corporate-governance red flag, even if resolved.
• Related-party transaction with Thingtrax (~£0.5m annually) where the CEO is a non-executive director 2025-11 HY report note 18 — small in absolute terms but should be monitored.
• Restated prior-period accounts following FRC Corporate Reporting Review of FY24 accounts — reclassification of £7.4m overdraft 2025-11 HY report note 1 — indicates historic financial-reporting weaknesses now corrected.
• Structurally very high effective tax rate (35–45%+) permanently constrains EPS.

Earnings vs. expectations

Looking back across the 5-year filing set, the pattern has been mixed with recent improvement: the December 2022 cancellation of a major supply contract triggered a profit warning; H1 24 guidance issued material-uncertainty going-concern warnings; FY24 and FY25 results were delivered largely in line with the revised, reduced expectations set through the year; the FY25 audit was delayed forcing the August 2025 suspension, but underlying trading exceeded guidance. HY26 and FY26 trading updates confirm "in line with management expectations" with medium-term targets hit ahead of plan. The trend is one of historically frequent misses, moving to a more recent pattern of meeting or narrowly beating a modest bar.

Conviction

Conviction: 3 (moderate).

• Anchoring the call: post-turnaround underlying EBITDA is well-supported by consistent H1 26 disclosure and April 2026 trading update; refinancing and pension deficit-recovery schedule are documented; ROS/ROCE both above medium-term targets provides a solid earnings floor.
• Limiting the call: the pension liability's true economic cost depends heavily on discount-rate assumptions that have swung the IAS 19 deficit £15m+ in single reporting periods; small-cap illiquidity and the recent 80× rally from a distressed base mean market pricing may still be volatile and unhinged from fundamentals.